Eucure Subsidiary Biocytogen Entered into a Worldwide License Agreement with Syncromune for the Development and Commercialization of Intratumoral Immunotherapy
Shots:
- Eucure to receive up front, development, and regulatory milestones along with royalties and other incentives upon the commercial value of Syncrovax combination therapy. Syncromune’s Syncrovax technology will generate a personalized autologous cancer vaccine using a patient’s cancer Ags
- Syncromune to get an exclusive right globally for the development & commercialization of intratumoral combination therapy containing YH002 & multiple other active ingredients
- Eucure holds all the global rights & will lead the drug manufacturing and supply. Syncromune will lead the clinical development & commercialization along with plans to develop combination therapies for metastatic breast, prostate, and lung cancer with a robust pipeline for 6 additional target cancers
Ref: Businesswire | Image: Eucure
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
